Evolus, Inc.

We are a global performance beauty company focused on the cash-pay aesthetic market, where consumers pay directly for medical products. Our customers are licensed aesthetic practitioners. We offer products in two major categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Our commercially available neurotoxin product is Jeuveau®, a proprietary 900 kilodalton (kDa) purified botulinum toxin type A formulation. It is indicated for the temporary improvement of moderate to severe glabellar lines (frown lines) in adults. Jeuveau® is an alternative to BOTOX (onabotulinumtoxinA) and is supported by our TRANSPARENCY global clinical program, which involved over 2,100 patients and included a head-to-head Phase III study comparing Jeuveau® and BOTOX. Jeuveau® is currently available in the United States, Canada, certain European markets, and Australia, with plans for expansion into additional European markets. Our HA gel product line is Evolysse™, which uses first-generation cold technology. This collection of injectable HA gels includes products for various applications such as mid-face, nasolabial folds, lips, and eyes.